Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07313891) titled 'A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT' on Dec. 29, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Relmada Therapeutics, Inc.
Condition:
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Bladder (Urothelial, Transitional Cell) Cancer
Urothelial Carcinoma Bladder
Urologic Cancer
Intervention:
Drug: NDV-01 (sustained-release gemcitabine-docetaxel)
Recruitment Stat...